AbCellera Biologics Inc. (NASDAQ:ABCL)
| Market Cap | 3.72B+97.6% |
| Revenue (ttm) | n/a+101.3% |
| Net Income | n/a+0.6% |
| EPS | n/a+3.6% |
| Shares Out | 305.38M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,025,789 |
| Open | 12.54 |
| Previous Close | 12.83 |
| Day's Range | 12.09 - 12.63 |
| 52-Week Range | 2.75 - 15.02 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 14.75(+21.00%) |
| Earnings Date | n/a |
AbCellera Biologics Inc. has a live Insider Score.
Scored on 4 qualifying trades from 3 insiders in the last 90 days.
About ABCL
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ABCL stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ABCL holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ABCL's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ABCL Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ABCL patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ABCL from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ABCL
| ETF | Est. Holding Size |
|---|---|
| IBBiShares Biotechnology ETF | $24.20M |
| IDNAiShares Genomics Immunology and Healthcare ETF | $8.36M |
| SPDWState Street SPDR Portfolio Developed World ex-US ETF | $7.49M |
| ONEQFidelity Nasdaq Composite Index ETF | $1.14M |
| AVUSAvantis U.S. Equity ETF | $852.26K |
| BBCVirtus Biotech Clinical Trials ETF | $796.36K |
Estimated from each fund’s disclosed top holdings × AUM
ABCL Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ABCL’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score